We will be comparing the differences between XBiotech Inc. (NASDAQ:XBIT) and Akari Therapeutics Plc (NASDAQ:AKTX) as far as risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership are concerned. The two businesses are rivals in the Biotechnology industry.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Akari Therapeutics Plc||N/A||0.00||16.47M||-1.68||0.00|
We can see in table 1 the earnings per share, top-line revenue and valuation of XBiotech Inc. and Akari Therapeutics Plc.
Table 2 demonstrates the net margins, return on assets and return on equity of XBiotech Inc. and Akari Therapeutics Plc.
|Net Margins||Return on Equity||Return on Assets|
|Akari Therapeutics Plc||0.00%||-207.2%||-119%|
Risk & Volatility
A 0.31 beta indicates that XBiotech Inc. is 69.00% less volatile compared to Standard and Poor’s 500. Competitively, Akari Therapeutics Plc’s 496.00% volatility makes it more volatile than Standard and Poor’s 500, because of the -3.96 beta.
The Current Ratio and a Quick Ratio of XBiotech Inc. are 9.3 and 9.3. Competitively, Akari Therapeutics Plc has 2 and 2 for Current and Quick Ratio. XBiotech Inc.’s better ability to pay short and long-term obligations than Akari Therapeutics Plc.
Insider and Institutional Ownership
Roughly 13.2% of XBiotech Inc. shares are held by institutional investors while 5.6% of Akari Therapeutics Plc are owned by institutional investors. 37.5% are XBiotech Inc.’s share held by insiders. Comparatively, 57.08% are Akari Therapeutics Plc’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Akari Therapeutics Plc||0.51%||-8.94%||5.79%||-4.18%||-5.66%||16.57%|
For the past year XBiotech Inc. was more bullish than Akari Therapeutics Plc.
XBiotech Inc. beats on 5 of the 6 factors Akari Therapeutics Plc.
XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The companyÂ’s lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barrÃ© syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.